Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.45 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 7/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | DAO | P14920 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27869200 | 0.87 | CSNK2A2 (0.40) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL6919868 | 0.85 | HDAC3 (0.43) | HPGDL3MBTL1MAPK1ATMTSHR | |
| SCHEMBL16901555 | 0.84 | HPGD (0.54) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL13545966 | 0.83 | USP2 (0.49) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL23022514 | 0.81 | CSNK2A2 (0.41) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL2063896 | 0.81 | HPGD (0.40) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL7836036 | 0.79 | CYP4A11 (0.44) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL13546197 | 0.78 | KDM4E (0.39) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL7835865 | 0.78 | CSNK2A2 (0.38) | CSNK2A2KDRCSNK2BCSNK2A1HPGD | |
| SCHEMBL261464 | 0.77 | CSNK2A2 (0.45) | CSNK2A2KDRCSNK2BCSNK2A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2507228-B1 | NOVEL SPIROPIPERIDINE COMPOUNDS | LILLY CO ELI (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2507228-B1 | NOVEL SPIROPIPERIDINE COMPOUNDS | LILLY CO ELI (US) | 2014-11-05 | — | — | EP | disclosed |
| US-8822486-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822486-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| US-8822486-B2 | Spiropiperidine compounds | ELI LILLY AND COMPANY (US) | 2014-09-02 | — | — | US | disclosed |
| EP-2507228-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | Eli Lilly and Company (US) | 2012-10-10 | — | — | EP | disclosed |
| US-20120220616-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220616-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220616-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011066183-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011066183-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2011-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220616-A1 | NOVEL SPIROPIPERIDINE COMPOUNDS | REN, SLC5A1, SLC5A2 | CSNK2A2 1091/4885KDR 3338/4885CSNK2B 1011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.